A B S T R A C T It has been suggested that the hyperglucagonemia observed in diabetic animals and man may be due to an impairment of glucose uptake and metabolism by the a-cells resulting in a decreased production of ATP. To test this hypothesis glucose, ATP, glucagon, and insulin were measured in pancreatic islets of normal and alloxan or streptozotocin diabetic rats. Two experimental approaches were used. In the first, the pancreas was perfused in vitro for assessing insulin and glucagon release due to 10 mM amino acids with and without 5 mM glucose. These perfusions were performed in the presence and absence of insulin. After perfusion, the pancreas was frozen and processed for analysis of islet glucose, ATP, insulin, and glucagon content. The second approach was to investigate the islet sucrose, urea, and glucose spaces together with ATP, insulin, and glucagon content in vivo in normal and in insulintreated and untreated streptozotocin diabetic rats.
content of a-cell islets was maintained for prolonged periods in the absence of glucose in contrast to mixed islets, composed primarily of 1cells, in which the ATP level decreased by 45% when glucose-free medium was perfused for sustained periods. Finally, insulin infused in high concentrations or administered to the diabetic animal had no effect on the glucose spaces or the ATP contents of normal or a-cell islets.
It can be calculated that in vivo the intracellular glucose level of islets from streptozotocin treated rats is approximately 15 mM. Since in normals an extracellular glucose concentration of this magnitude inhibits stimulated glucagon release completely, it would seem unlikely that a lack of intracellular glucose is the cause of the apparent glucose "blindness" of the a-cells in diabetes. In fact, in perfusion studies as little as 2.5 mM free intracellular glucose was sufficient to suppress glucagon secretion from diabetic a-cells. The results of the ATP measurements clearly eliminate a possible energy deficit of diabetic a-cells as cause of the apparent glucose resistance of a-cells.
INTRODUCTION
The hyperglucagonemia that occurs in severe diabetes in man, and in animals made diabetic with alloxan or streptozotocin, is not suppressed by high glucose, but is suppressed after insulin treatment (1) . On the basis of these observations, together with in vitro studies utilizing isolated islets, in which metabolic poisons seemed to interfere with glucose inhibition of glucagon secretion (2, 3) , it has been suggested that the hyperglycemic suppression of glucagon release in the normal islet results from enhanced glucose transport with a subsequent increase in energy metabolism within the a-cell, and that the glucose metabolism of these cells is an insulin-requiring process. Similarly, the lack of glucose suppression of glucagon release in the diabetic state decrease in glucose uptake by the a-cell with a concomitant decrease in ATP availability (4) . In a previous communication form this laboratory (5), it was demonstrated in both alloxan and streptozotocin diabetic rats that: (a) basal glucagon release from the isolated perfused pancreas (measured in the absence of an a-cell stimulus or inhibitor) was extremely low, about 1/10 the basal rates seen in controls; (b) the a-cells of both diabetic prototypes responded with a biphasic glucagon release to stimulation by an amino acid mixture; (c) the a-cell response to amino acids was reduced after both streptozotocin and alloxan as compared to controls; (d) glucose (5 mM) was a potent inhibitor of amino acid-induced glucagon secretion in both experimental types of diabetes in the virtual absence of insulin secretion; and (e) in alloxan diabetes a-cell stimulation by amino acids was inhibited by high levels of exogenous insulin, whereas glucagon secretion by the perfused pancreas of streptozotocin diabetic rats was resistant to insulin action under these conditions. It was concluded from this study that the basic mechanisms underlying modulation of glucagon secretion by glucose in vitro is largely insulin independent and that factors extrinsic to the pancreatic islets are the primary cause for the hyperglucagonemia observed in vivo.
The present communication is an extension of the above study. It was the objective during this part of our investigation to obtain basic information on parameters of energy metabolism of pancreatic a-cells by direct chemical analysis, rather than through indirect means. Glucose and ATP concentrations were determined in islets of normal, streptozotocin, and alloxan diabetic animals in an attempt to further elucidate the mechanism by which glucose might inhibit glucagon secretion. Quantitative histochemical methods were applied for this purpose, which allowed us to perform such measurements in islets from the pancreas rapidly sampled in vivo or after extracorporeal organ perfusion.
METHODS

Studies with the isolated perfused pancreas
The general preparation of the animals, the induction of diabetes by alloxan or streptozotocin, and the procedural details of the extracorporeal perfusion of the pancreas used in the biochemical portion of this study, have been presented previously, together with the data on a-and ,3-cell secretory functions (5) . The five different experimental protocols used in the perfusion studies are summarized in Fig. 1 . For further details, the preceeding paper may be consulted (5 On this regimen, which was continued for 2-3 wk, the animals decreased their daily urine volume and fluid intake and gained weight, whereas the nontreated diabetic animals lost weight continuously. At the time of sacrifice, the weight ofthe normal animals was 394±6 g (n = 8), that of the insulin-treated diabetic animals 288±6 g (n = 8), and that of the nontreated diabetic animals 224±6 g (n = 8). The animals received their last insulin 14 h before sacrifice. Unlike the in vitro study where all animals were fasted (5) , all animals in the in vivo study were allowed to feed to prevent hypoglycemic seizures, which were common in the insulin-treated group when these animals were fasted.
Blood and pancreas sampling and special treatment before sampling. Animals received atropine (0.1 mg/kg i.p.) and were anesthetized 30 min later by pentobarbital (30 mg/kg i.p.). The abdominal cavity was opened and the pancreas exposed. Heparin (30 USPU iv/kg body weight) was injected into the inferior vena cava together with the extracellular marker sucrose (0.1 ml of 1.5 M i.v./kg body weight) 5 min before sampling of the pancreas. The pancreas, with the spleen still attached, was quickly excised and frozen in Freon-12, cooled to its freezing point with liquid nitrogen. Blood was sampled from the pool accumulating in the peritoneal cavity after the pancreas had been removed. The blood was injected into tubes containing 500 KIU/ml Trasylol (FBA Pharmaceuticals, Inc., New York) and 1.25 mg EDTAI ml, and was kept on ice for no longer than 30 min. ' i plasma stored at -20°C until assayed. Insulin and glucagon were determined in plasma and islet samples by radioimmunoassay procedures described previously (5, 6) . Preparation of the pancreas for histochemical analysis. Sections of the pancreas were cut at -20°C in the cryostat 30,um thick and were submitted to freeze drying for three days at -40°to -35°C and then stored under vacuum at -20°C. Islets were then dissected with the aid of a stereomicroscope at low magnification without prior staining in a room that provided low humidity (50%) and constant temperature (18°C). The weights of the specimens were obtained with the quartz fiber fishpole balance (7, 8) .
Chemical analytical procedures. Plasma glucose, sucrose, and urea measurements were performed by fluorometric enzymatic assays. Islet contents of glucose, sucrose, urea, and ATP were determined by enzymatic fluorometry in combination with enzymatic cycling and an oil well technique, to gain the necessary sensitivity. Principles and procedural details of the methods have been described previously (7, 8) , except for urea. The present procedure is a modification of a method to be published elsewhere.' The enzymatic assay for urea is based on the liberation of NH3 from urea by urease, followed by the recording of the triphosphopyridine nucleotide (TPNH)2 dependent amination of aketo-glutarate by glutamic acid dehydrogenase. Details of this latter method are given below. To measure urea in plasma 1-3 ,ul of plasma are added to 1 ml of the following reagent: Tris-HCl buffer, 50 mM pH 7.7; ADP, 0.1 mM; a-keto-glutarate, 5 mM; TPNH, 25 ,uM; and nicotinamide, 20 mM. The two enzymes were added separately; 65 ,ug/ml of glutamic acid dehydrogenase as the first step, to allow correction for ammonia present in the plasma and reagent, followed by the addition of urease (3.2 ,ug/ml) in a second step for the specific assay of urea. Urea standards ranging from 1.5 to 9.5 nmol were processed in the same way. The microassay was performed with an oil well method (8) (7, 8) . For this purpose, the droplet was transferred quantitatively to 50 ,ul of cycling reagent (8) . The two cycling enzymes were adjusted to result in an amplification of about 2,000-fold. The 6-P-gluconate formed in the process of cycling was measured by enzymatic fluorometry (7, 8) . Urea 4 Significantly different, comparing diabetic and diabetic + insulin, P < 0.01 for weight, P < 0.05 for glucose, and P < 0.001 for insulin. § Degree of significance of the difference of plasma values of diabetic animals as compared to normals in the respective study.
centration (mmol/liter), and 0.92 = correction for plasma solids. Since sucrose is confined to the extracellular space, the intracellular glucose space is the difference between the total glucose space minus the sucrose space. All spaces are expressed in nanoliters per microgram of dry tissue.
RESULTS
Criteria for defining diabetes. The animals used in this project were defined as being diabetic when the plasma glucose in the untreated state was greater than 6 SD from the mean of the corresponding control animals, as previously discussed in detail (5) . These animals also demonstrated markedly depressed plasma insulin and significantly elevated plasma gltucagoi levels (see Table I for the in vivo study and Ref.
5 for the perfusion study). In the in vivo study, the diabetic animals, whether treated with insulin or not, had significantly higher plasma glucose than controls and elevated plasma glucagon levels. The plasma glucagon of the insulin treated animals was lower than that of the untreated, but this difference was not statistically significant. Insulin significantly lowered the plasma glucose of the treated animals. In the untreated diabetics, plasma insulin was barely detectable, while in the treated diabetics, it was indistinguishable from the plasma insulin of the controls. The severity of the diabetes induced by alloxan and streptozotocin is further documented by the results of the perfusion study previously published (5 (Table II) . Total insulin content in the islets of the diabetic animals was 5-6% of the normal, while the ratio of total glucagon content between normal mixed a-and ,3cell islets and that of the a-cell islets varied between 4 and 10 (Table II) . This ratio is further evidence that the tissue being analyzed in the diabetic pancreas contained primarily a-cells, since it has been previously demonstrated morphologically that the a-cell mass of the rat pancreas consists of 10-25% of the total islet cell mass (9, 10) . Preliminary determinations of the islet volume revealed a decrease in diabetes as defined here to at least one-third of the control value (11), consistent with the results published by others (9) .
In vitro studies is not clear. First, the method used here to measure glucose might react with some form of bound glucose, which is mobilized by the mild acidic treatment in preparation of the specific enzymatic microassay (8) . It is unlikely that the glycogen is the source ofbound glucose, since the glycogen levels ofthe islets are low (8) . Second, the higher glucose content in the a-cell islets may be explained by impeded diffusion of free glucose out of the a-cell. The glucose pool to be dissipated is substantial, due to the prolonged and excessive hyperglycemia in vivo (see below).
Perfusion with 20 mM glucose for 30 min, followed by aglycemic perfusion for 30 min, resulted in islet glucose concentrations which were indistinguishable from perfusions with the 10-mM amino acid mixture alone, indicating that the 30-min perfusion with the amino acid mixture had no effect on the basal glucose content of the islets. Again, the diabetic islets had significantly more glucose than the normal (normal 1.8+0.1, alloxan 3.1+0.4, and streptozotocin 4.2+1.2, P <0.05, for both diabetic prototypes vs. normal; Protocol 5, Table II) .
ATP content of normal and diabetic islets from the perfused pancreas. After pancreas perfusions without glucose, the ATP content of normal islets was significantly less than that found in a-cell islets of alloxan and streptozotocin diabetic animals (normal 7.6±0.5, alloxan diabetic 13.7+0.9, and streptozotocin diabetic 13 .3+0.9, P < 0.001 for both diabetic prototype vs.
normal; Protocol 1, Table II ). Addition of5 mM glucose to the perfusate significantly increased the ATP content of the normal islets (7.6±0.5 without glucose to 13.4±0.8 mmol/kg dry tissue with glucose, P < 0.001), but had no effect on ATP content of a-cell islets (compare Protocols 1 and 2, Table II ). The increase in ATP in the normal islets, with glucose in the perfusion media, attained the level of that observed in the diabetic islets with or without glucose in the perfusate.
Addition of insulin to the perfusate, in the presence or absence of glucose, had no significant effect on the ATP content of normal or diabetic islets. (Compare Protocols 1 and 3, and 2 and 4, Table II) . Although not significant, there was a tendency towards elevated ATP levels when normal and diabetic pancreases were perfused with glucose plus insulin (compare Protocols 2 and 4, Table II) .
Perfusion with 20 mM glucose for 30 min, followed by aglycemic perfusion for 30 min, resulted in islet ATP concentrations which were indistinguishable from those observed with the 10-mM amino acid mixture, suggesting that the amino acids had little effect in the maintenance of the ATP content of normal or diabetic islets (Protocol 5, Table II (Table  IV) . The islet sucrose and urea spaces of the three groups were similar, while the total and intracellular glucose spaces of the normal islets were the largest (Table IV) 4 Significantly different (P < 0.001) from the normal animals.
1198
F. Matschinsky, A. Pagliara, S. Stillings, and B. Hover < 0.001 for both groups, compared to normal). The intracelltular gltucose space was also substantially smaller in the diabetic animals (normal 2.04+0.11, uintreated diabetic 0.59+0. 10, and treated diabetic 0.63 ±0.08 nl/,ug dry tissue, P < 0.001, for both groups, compared to normal). Islet ATP, insulin, and glucagon content in normal, untreated, and insulin-treated diabetic animals. Compared to diabetics, normal islets had a small, but significantly higher content of ATP (normal 13.51 ±0.15, untreated diabetic 10.76±0.30, and treated diabetic 11.61±0.22 mmol/kg dry tissue, P < 0.01 for both diabetic groups compared to normal) ( Table V) . Insulin content in both groups of diabetic animals were approximately 3% of the normal islets, while the glucagon content in the diabetic islets was increased eightfold over that of the normal (Table V) . DISCUSSION The present study has uncovered some characteristic features of glucose and energy metabolism of pancreatic a-cells. These cells are less accessible to glucose than 13-cells, as indicated by the relatively small intracellular glucose space of a-cell islets most readily apparent in the in vivo studies. Further, the ATP content of a-cell islets is maintained for prolonged periods in the absence of extracellular glucose in contrast to the mixed islets composed, primarily, of ,/cells, in which the ATP level drops when glucosefree perfusion media are used for sustained periods. Finally, exogenous insulin, at high levels, has no detectable effect on the glucose spaces and only marginal, if any, influence on the ATP content of normal or a-cell islets.
Since the present information is derived from steady-state measurements, it is obviously not possible to decide whether glucose or insulin have any effect on the turnover of ATP or whether insulin increases the rate ofglucose transport into islet cells. The cardinal question, whether there is an energy shortage of a-cells in the diabetic state, seems to be clearly answered, however, by these investigations. There is sufficient ATP and glucose present in the diabetic islet. Since the total glucose content in islets, from streptozotocin-treated rats with a mean plasma glucose of 32.5 mM, measured 43.2 mmol/kg dry tissue, it follows (based on the information available in 
